Wupi Powder Veterinary Grade API is a crystalline active pharmaceutical ingredient powder supplied for further manufacture into tablets, injections, capsules, oral powders, granules, premixes, and solutions. The product is released under supplier designation WP-VG-API/2201. Two derived grades are available: WP-VG-API/2201-M, a micronized grade for injectable and low-dose solid dosage forms, and WP-VG-API/2201-P, a premix grade co-processed with 1% precipitated silica. Wupi Powder is not a sterile product; injectable manufacturing requires terminal sterilization or aseptic filtration after dissolution. The base grade is milled and sieved to control agglomerates; the micronized grade is produced by jet milling with nitrogen to avoid thermal degradation; the premix grade is low-shear blended with silica to preserve particle-size distribution.

Release specifications include assay 98.0–102.0% on the dried basis by HPLC, loss on drying not more than 0.5%, residue on ignition not more than 0.1%, and total heavy metals not more than 20 µg/g. The injectable-dedicated grade carries a bacterial endotoxin limit of 0.15 EU/mg by Ph. Eur. 2.6.14 or USP <85>. Residual solvents are controlled under ICH Q3C maintenance decisions; Class 1 solvents are specified as absent, and Class 2 solvents are limited to option-2 concentration limits in Ph. Eur. 5.4. The certificate of analysis includes X-ray powder diffraction identity confirmation, HPLC peak purity, and laser diffraction particle-size data. These controls separate Wupi Powder from non-pharmacopoeial feed-grade powders, which may lack endotoxin, polymorph, and residual solvent testing.

What Distinguishes Wupi Powder from Generic Veterinary API Powders?

Generic chemical-grade powders of the same nominal active substance are often sold with limited certificate parameters such as assay, moisture, and appearance. Wupi Powder is released under a veterinary-specific control strategy that includes polymorph identity by XRPD, bacterial endotoxin testing for parenteral-grade material, residual solvent analysis by headspace gas chromatography, and particle-size distribution by laser diffraction according to ISO 13320-1:2020. For tablet and capsule applications, the base grade is controlled for bulk density in the range 0.45–0.65 g/cm³ and tapped density 0.60–0.80 g/cm³ by USP <616> Method I. The premix grade is co-processed with 1% precipitated silica, which reduces sieve-blocking particle aggregates larger than 500 µm to not more than 0.5% of total mass. Uncontrolled powders frequently exhibit broad agglomerate distributions and higher tap density variability, leading to segregation during bin transfer and dosing variation in rotary tablet presses.

The micronized grade WP-VG-API/2201-M differs from the base grade by controlled particle-size reduction; laser diffraction data show D90 ≤ 20 µm and D50 5–10 µm, improving dissolution kinetics in aqueous media under Ph. Eur. 2.9.3 paddle conditions. In contrast, the base grade without micronization may dissolve more slowly in low-volume oral solutions, and published dissolution data for this specific veterinary active in compendial media is limited. Therefore, the choice of grade should be driven by a product-specific dissolution method rather than by general particle-size claims.

In solid dosage production, the base Wupi Powder grade is usually dry-mixed with lactose monohydrate or microcrystalline cellulose and granulated in a fluid bed granulator with inlet air temperature 55–65°C and product temperature not exceeding 40°C. The granulator is operated with a filter bag shake cycle of 60 s intervals; extended drying cycles above 2.0% residual moisture produce overgranulated fines that segregate in hoppers. A final blend with 0.5–1.0% magnesium stearate is acceptable when the lubricant is screened through a 500 µm mesh and blended for 3–5 min in a diffusion mixer. Longer lubrication reduces tablet hardness and increases friability above 1.0% in Ph. Eur. 2.9.7 testing.

Tablets of 200 mg target weight produced on a 16-station rotary press with 8 mm round concave tooling demonstrate consistent weight variation below 3.0% when the powder blend bulk density is held within 0.45–0.55 g/cm³. Compression force is typically set between 5 kN and 12 kN, with precompression at 2–4 kN. These conditions reduce capping and lamination in formulations containing more than 25% Wupi Powder. The compendial uniformity requirements of USP <905> and Ph. Eur. 2.9.40 remain the minimum acceptance criteria. If batch-to-batch bulk density varies by ±0.05 g/cm³, tablet weight can shift by up to 3.0% on rotary presses with force feeders; this is mitigated by pre-compacting the base powder or selecting the micronized grade for low-dose formulations.

When Fluid Bed Granulation Triggers Fines Migration and Segregation

Fines migration occurs when the inlet air distribution plate of a fluid bed granulator is contaminated with retained material from previous batches or when air velocity is too high for the wet mass. For Wupi Powder granulations containing 10–20% active substance, inlet air velocity of 1.5–2.5 m/s through the product chamber is used; velocities above 3.0 m/s entrain fine particles into the filter bag, producing active-content variability greater than 5.0% relative standard deviation. The granulation endpoint is controlled by product moisture of 1.5–2.5% and by a torque value on the chopper motor, which is recorded against a batch-specific set point. If torque drops below the validated range, the granulation is terminated to avoid overwetted lumps larger than 2,000 µm, which cannot be dry-milled without thermal stress.

After granulation, the material is passed through an oscillating granulator with a 0.8 mm or 1.0 mm screen; the smaller screen is used when API particle size D90 exceeds 50 µm. For premix and granule applications, geometric dilution in a V-blender with 50–60% fill level and 15–20 min mixing time is used. Mixing beyond 25 min at high speed can increase static charge and fines segregation, particularly below 30% RH. Pre-drying is required when storage relative humidity exceeds 60% RH, because moisture uptake above 0.5% causes sticking to tablet punch faces and sieve blinding in cone mills.

Residual Solvent, Endotoxin, and Polymorph Control in Injectable-Grade Material

Injectable solutions prepared from Wupi Powder are not intrinsically sterile. The API is dissolved in Water for Injection at a concentration determined by the final product monograph; if solubility is insufficient, co-solvents such as propylene glycol or ethanol are introduced. The solution pH is adjusted with hydrochloric acid or sodium hydroxide, and the bulk solution is passed through a 0.22 µm sterilizing-grade polyethersulfone or polyvinylidene fluoride membrane filter. For heat-sensitive formulations, aseptic filtration is used; for thermostable formulations, terminal sterilization at 121°C for 15 min is preferred. The injectable-grade Wupi Powder has a bacterial endotoxin limit of 0.15 EU/mg; however, the final solution must meet the limit defined in the relevant veterinary monograph, which may be lower after dilution. Particulate matter is controlled by filtration and by the API’s controlled particle-size distribution. The micronized grade WP-VG-API/2201-M has D90 ≤ 20 µm and D50 5–10 µm, reducing dissolution time in aqueous media under Ph. Eur. 2.9.3 test conditions. Polymorphic identity is confirmed by XRPD because conversion to an amorphous or unstable crystalline form during milling can alter dissolution and parenteral bioavailability.

Residual solvent control is critical for injectable applications. The manufacturer’s headspace gas chromatographic method follows Ph. Eur. 2.4.24 and reports Class 2 solvent levels against the concentration limits of ICH Q3C option 2. Batches with methanol, acetonitrile, or dichloromethane above compendial thresholds are rejected. The powder is incompatible with strong oxidising agents and should not be dry heat sterilised in its solid state. Contact with silicone oil or high-extractable tubing should be avoided because subvisible particulate counts may exceed Ph. Eur. 2.9.19 limits for parenteral preparations.

For capsule filling, Wupi Powder is usually blended with lactose monohydrate and pregelatinised starch and passed through a 0.5 mm sieve. Capsule filling on dosator-type machines requires tapped density above 0.60 g/cm³; if tapped density falls below 0.55 g/cm³, powder bridging in the dosing chamber produces weight variation above 3.0%. The premix grade is not recommended for hard gelatin capsules unless the silica content is accounted for in the dissolution specification. For oral powders and granules, the API is distributed by geometric dilution to achieve a relative standard deviation below 5.0% in mixer uniformity testing. These processing limits are drawn from batch record observations on production-scale equipment; published data for this specific Wupi Powder formulation is limited, and site-specific process validation is required under VICH GL18(R2).

Premix and Oral Solution Lines Require Moisture, Carrier, and Dissolved Oxygen Control

Premix manufacturing with Wupi Powder requires control of carrier particle size and moisture. Lactose monohydrate or corn starch carriers are conditioned to ≤ 0.5% moisture before mixing. The API is first blended with an equal mass of carrier, then this preblend is passed through a 300 µm cone mill to break agglomerates, and finally mixed with the remaining carrier in a ribbon blender. The ribbon blender is operated at 15–20 rpm for 10–15 min; higher speeds cause segregation of fine API to the top of the blend. The premix grade WP-VG-API/2201-P, containing 1% precipitated silica, reduces this sensitivity and allows direct addition to pelleted feed matrices without electrostatic clumping.

Oral solutions prepared from Wupi Powder use Water for Injection or purified water; the pH and dissolved oxygen are controlled because the molecule undergoes oxidation in aqueous solution when headspace oxygen exceeds 2.0 mg/L. Nitrogen sparging to 0.5 mg/L dissolved oxygen and amber glass packaging with oxygen-barrier closures are required for liquid products stored longer than 12 months at 25°C/60% RH. The pH specification for oral solutions is usually 4.0–7.0; above 8.0, hydrolysis kinetics accelerate. Avoid combination with amine-based additives in aqueous solutions because pH shifts above 8.0 increase degradation to unspecified related substances above 0.5% in accelerated stability studies. If a chelating agent is required, disodium edetate is added at 0.1% w/v, provided that compatibility with the final container closure is confirmed. Storage of the base API should be at 15–25°C in moisture-tight double polyethylene-lined fiber drums; the micronized injectable grade is stored at 2–8°C to preserve particle-size distribution and polymorph identity.

Switching between Wupi Powder and other veterinary active substances on shared equipment requires cleaning validation because the micronized powder has high adhesion to stainless steel contact surfaces. Cleaning protocols using warm purified water at 40–50°C followed by 0.1 mol/L sodium hydroxide solution are validated by swab recovery and rinse sampling. Swab limits are set according to health-based exposure limits as described in VICH GL18(R2) and EMA/CVMP/187/2010. Published data for Wupi Powder carry-over thresholds is limited; each site must establish its own acceptable residue limits from toxicological data.